Syra Health Faces Nasdaq Delisting Warning
Ticker: SYRA · Form: 8-K · Filed: Aug 15, 2024 · CIK: 1922335
| Field | Detail |
|---|---|
| Company | Syra Health Corp (SYRA) |
| Form Type | 8-K |
| Filed Date | Aug 15, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $2,500,000, $7.5, $9.5 m |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, nasdaq
Related Tickers: SYRA
TL;DR
Nasdaq's coming for Syra Health's listing - they got a warning!
AI Summary
Syra Health Corp. announced on August 13, 2024, that it received a notice from the Nasdaq Stock Market indicating a failure to meet continued listing requirements. The company is currently evaluating its options to regain compliance and avoid delisting.
Why It Matters
This notice could significantly impact Syra Health's stock liquidity and investor confidence, potentially leading to a delisting from the Nasdaq.
Risk Assessment
Risk Level: high — Receiving a delisting notice from a major exchange like Nasdaq presents a significant risk to the company's operations and stock value.
Key Players & Entities
- Syra Health Corp. (company) — Registrant
- Nasdaq Stock Market (company) — Exchange issuing notice
- August 13, 2024 (date) — Date of notice
FAQ
What specific continued listing rule did Syra Health Corp. fail to meet?
The filing does not specify the exact continued listing rule that Syra Health Corp. failed to meet, only that it received a notice of failure to satisfy such a rule.
What is the deadline for Syra Health Corp. to regain compliance with Nasdaq listing standards?
The filing does not state a specific deadline for Syra Health Corp. to regain compliance.
What actions is Syra Health Corp. considering to address the delisting notice?
Syra Health Corp. is evaluating its options to regain compliance with the listing requirements.
Has Syra Health Corp. previously received any warnings from Nasdaq?
This filing does not provide information on any prior warnings from Nasdaq.
What is the potential impact of this notice on Syra Health Corp.'s stock trading?
A failure to meet listing requirements could lead to the delisting of Syra Health Corp.'s securities from the Nasdaq Stock Market, impacting trading.
Filing Stats: 739 words · 3 min read · ~2 pages · Grade level 12 · Accepted 2024-08-15 17:29:01
Key Financial Figures
- $0.001 — hich registered Class A Common Stock, $0.001 par value SYRA The Nasdaq Stock Mar
- $2,500,000 — es the Company to maintain a minimum of $2,500,000 in stockholders' equity for continued l
- $7.5 — y anticipates full-year 2024 revenue of $7.5 to $9.5 million, representing a growth
- $9.5 m — pates full-year 2024 revenue of $7.5 to $9.5 million, representing a growth of 36%-73%
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-24-032692.txt ( ) — 207KB
- syra-20240813.xsd (EX-101.SCH) — 3KB
- syra-20240813_lab.xml (EX-101.LAB) — 33KB
- syra-20240813_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SYRA HEALTH CORP. Date: August 15, 2024 By: /s/ Deepika Vuppalanchi Deepika Vuppalanchi Chief Executive Officer -3-